|
Real-time Estimate
Cboe BZX
12:46:28 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 4.185 USD | +1.82% |
|
+13.65% | +78.18% |
| 10-14 | Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December | MT |
| 10-14 | Rezolute, Inc. Completes Enrollment In Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism | CI |
Company Valuation: Rezolute, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 108.5 | 72.92 | 228.6 | 387.2 | 543.2 | 431.1 | - | - |
| Change | - | -32.78% | 213.56% | 69.34% | 40.3% | -20.64% | - | - |
| Enterprise Value (EV) | 108.5 | 72.92 | 148.6 | 387.2 | 543.2 | 431.1 | 431.1 | 431.1 |
| Change | - | -32.78% | 103.82% | 160.53% | 40.3% | -20.64% | 0% | 0% |
| P/E | -1.43x | -1.96x | -3.23x | -4.55x | -6.93x | -5.82x | -7.95x | -11.3x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | -0.1x | 0.2x | 0.3x | 1x | 0.3x | 0.4x |
| Capitalization / Revenue | - | - | - | - | - | 206x | 7.97x | 2.77x |
| EV / Revenue | - | - | - | - | - | 206x | 7.97x | 2.77x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -5.26x | -6.96x | 29.5x |
| EV / FCF | - | - | -0x | -0x | -0x | -5.95x | -6.6x | -19.7x |
| FCF Yield | - | - | -25.1% | -17.8% | -11.9% | -16.8% | -15.2% | -5.07% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.26 | -1.01 | -1.33 | -0.98 | -0.75 | -0.7064 | -0.517 | -0.3625 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 2.095 | 54.09 | 155.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -41.84 | -55.99 | -70.42 | -79.89 | -82.97 | -81.9 | -61.98 | 14.63 |
| Net income 1 | -41.06 | -51.79 | -68.46 | -74.41 | -77.59 | -79.49 | -59.93 | 19.29 |
| Net Debt | - | - | -80.02 | - | - | - | - | - |
| Reference price 2 | 3.230 | 1.980 | 4.300 | 4.460 | 5.200 | 4.110 | 4.110 | 4.110 |
| Nbr of stocks (in thousands) | 33,583 | 36,828 | 53,173 | 86,815 | 104,467 | 104,897 | - | - |
| Announcement Date | 9/15/22 | 9/14/23 | 9/19/24 | 9/17/25 | 9/24/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.82x | - | - | - | 431M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 23.61x | 26.33x | 15.57x | 0.34% | 38.09B | |
| Weighted average by Cap. | 26.51x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RZLT Stock
- Valuation Rezolute, Inc.
Select your edition
All financial news and data tailored to specific country editions
